Portfolio company HilleVax was acquired by Xoma Royalty in August 2025.
HilleVax is a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, specifically targeting norovirus infections
HilleVax is a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, specifically targeting norovirus infections.